Cargando…

Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review

SIMPLE SUMMARY: PDAC is one of the most malignant tumors and its treatment, whether surgery or chemotherapy, has shown poor results. Resistance to gemcitabine and other chemotherapeutic drugs is an essential factor in this failure. This review analyzes the molecular causes of gemcitabine resistance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koltai, Tomas, Reshkin, Stephan Joel, Carvalho, Tiago M. A., Di Molfetta, Daria, Greco, Maria Raffaella, Alfarouk, Khalid Omer, Cardone, Rosa Angela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139729/ https://www.ncbi.nlm.nih.gov/pubmed/35626089 http://dx.doi.org/10.3390/cancers14102486

Ejemplares similares

Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as Therapeutic Approaches
por: Carvalho, Tiago M. A., et al.
Publicado: (2021)

Role of pH in Regulating Cancer Pyrimidine Synthesis
por: Alqahtani, Saad Saeed, et al.
Publicado: (2022)

Targeting the Stromal Pro-Tumoral Hyaluronan-CD44 Pathway in Pancreatic Cancer
por: Koltai, Tomas, et al.
Publicado: (2021)

Integrin-Linked Kinase Links Integrin Activation to Invadopodia Function and Invasion via the p(T567)-Ezrin/NHERF1/NHE1 Pathway
por: Greco, Maria Raffaella, et al.
Publicado: (2021)

Extracellular Matrix Composition Modulates the Responsiveness of Differentiated and Stem Pancreatic Cancer Cells to Lipophilic Derivate of Gemcitabine
por: Forciniti, Stefania, et al.
Publicado: (2020)

Extracellular Matrix Collagen I Differentially Regulates the Metabolic Plasticity of Pancreatic Ductal Adenocarcinoma Parenchymal Cell and Cancer Stem Cell
por: Tavares-Valente, Diana, et al.
Publicado: (2023)

Cancer Associated Fibroblast (CAF) Regulation of PDAC Parenchymal (CPC) and CSC Phenotypes Is Modulated by ECM Composition
por: Cannone, Stefania, et al.
Publicado: (2022)

Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer
por: Koltai, Tomas, et al.
Publicado: (2019)

The Role of Sodium Hydrogen Exchanger 1 in Dysregulation of Proton Dynamics and Reprogramming of Cancer Metabolism as a Sequela
por: Cardone, Rosa Angela, et al.
Publicado: (2019)

ECM Composition Differentially Regulates Intracellular and Extracellular pH in Normal and Cancer Pancreatic Duct Epithelial Cells
por: Di Molfetta, Daria, et al.
Publicado: (2023)

The Prime and Integral Cause of Cancer in the Post-Warburg Era
por: Harguindey, Salvador, et al.
Publicado: (2023)

Of mitochondrion and COVID-19
por: Alfarouk, Khalid Omer, et al.
Publicado: (2021)

Metabolic Shifts as the Hallmark of Most Common Diseases: The Quest for the Underlying Unity
por: Schwartz, Laurent, et al.
Publicado: (2021)

Hydrogen Ion Dynamics as the Fundamental Link between Neurodegenerative Diseases and Cancer: Its Application to the Therapeutics of Neurodegenerative Diseases with Special Emphasis on Multiple Sclerosis
por: Harguindey, Salvador, et al.
Publicado: (2022)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma
por: Palam, L R, et al.
Publicado: (2015)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
por: Shao, Feng, et al.
Publicado: (2018)

Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma
por: Nishi, Hidemi, et al.
Publicado: (2023)

The possible role of methylglyoxal metabolism in cancer
por: Alfarouk, Khalid O., et al.
Publicado: (2021)

Lipocalin2 Promotes Invasion, Tumorigenicity and Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
por: Leung, Lisa, et al.
Publicado: (2012)

Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
por: Middleton, Gary, et al.
Publicado: (2016)

Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation
por: Li, Junjie, et al.
Publicado: (2018)

Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma
por: Miller, Aubrey L., et al.
Publicado: (2020)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma
por: Takagi, Tadataka, et al.
Publicado: (2023)

Curing cancer? Further along the new pH-centric road and paradigm
por: Harguindey, S., et al.
Publicado: (2018)

Role of Stromal Cells in Determining Tumor and Cancer Stem Cell Behaviors and Therapeutic Response
por: Reshkin, Stephan J., et al.
Publicado: (2020)

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
por: Zhu, Zhou, et al.
Publicado: (2023)

The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma
por: Park, Joo Kyung, et al.
Publicado: (2016)

Survivin Splice Variant 2β Enhances Pancreatic Ductal Adenocarcinoma Resistance to Gemcitabine
por: Fuller, Ryan N, et al.
Publicado: (2022)

Extracellular Vesicles Inhibit the Response of Pancreatic Ductal Adenocarcinoma Cells to Gemcitabine and TRAIL Treatment
por: Rimmer, Ella, et al.
Publicado: (2022)

Pancreatic ductal adenocarcinoma cells regulated the gemcitabine‐resistance function of CAFs by LINC00460
por: Zhu, Xiao‐Xu, et al.
Publicado: (2022)

Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells
por: Kan, Shin, et al.
Publicado: (2015)

Contribution of Cholesterol and Oxysterols in the Physiopathology of Cataract: Implication for the Development of Pharmacological Treatments
por: Vejux, Anne, et al.
Publicado: (2011)

Obesity in Prader–Willi syndrome: physiopathological mechanisms, nutritional and pharmacological approaches
por: Muscogiuri, G., et al.
Publicado: (2021)

Physiopathology of shock
por: Bonanno, Fabrizio Giuseppe
Publicado: (2011)

The Physiopathology of Cancer
por: Velardo, Joseph Thomas
Publicado: (1959)

MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
por: Mikamori, Manabu, et al.
Publicado: (2017)

Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma
por: Acuna-Villaorduna, Ana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r79si1i4fh3inn5qs0rmlaeur5